Pharmacokinetics of repeated doses of misoprostol

Human Reproduction

Volumn 24, Issue 8, 2009, Pages 1862-1869

  Tang, Oi Shan ^a   Schweer, Horst ^b   Lee, Sharon W H ^a   Ho, Pak Chung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Misoprostol; Pharmacokinetics; Sublingual; Vaginal

Indexed keywords

15 DEOXY 16 HYDROXY 16 METHYLPROSTAGLANDIN E1; DRUG METABOLITE; MISOPROSTOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; PREGNANCY TERMINATION; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SUCTION DRAINAGE; VAGINA BLEEDING;

EID: 67651092226     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dep108     Document Type: Article

References (15)

1. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod 2004;19:81-84.
2. Aronsson A, Fiala C, Stephansson O, Granath F, Watzer B, Schweer H, Gemzell-Danielsson K. Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol. Hum Reprod 2007;22:1912-1918.
3. Ashok PW, Penney GC, Flett GMM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998;13:2962-2965.
4. Cicinelli E, Schonauer LM, Galantino P, Matteo MG, Cassetta R, Pinto V. Mechanisms of uterine specificity of vaginal progesterone. Hum Reprod 2000a;15(Suppl 1):159-165.
5. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000b;95:403-406.
6. El-Refaey H, Calder L, Wheatley DN, Templeton A. Cervical priming with prostaglandin E1 analgues, misoprostol and gemeprost. Lancet 1994; 343:1207-1209.
7. El-Refaey H, Rajasekar D, Abdalia M, Calder L, Templeton A. Induction of abortion with mifepristone and oral or vaginal misoprostol. N Engl J Med 1995;332:983-987.
8. Ho PC, Ngai SW, Liu KL, Wong GCY, Lee SWH. Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy. Obstet Gynaecol 1997;90:735-738.
9. Ngai SW, Tang OS, Lao T, Ho PC, Ma HK. Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy. Hum Reprod 1995;10:1220-1222.
10. Ngai SW, Au Yeung KC, Lao T, Ho PC. Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomized study. Br J Obstet Gynaecol 1996;103:1120-1123.
11. Tang OS, Schweer H, Seyberth HW, Lee SWH, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17:332-336.
12. Tang OS, Chan CCW, Ng EHY, Lee SWH, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 2003;18:2315-2318.
13. Tang OS, Lau WNT, Chan CCW, Ho PC. A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004;111:1001-1005.
14. Wong KS, Ngai CS, Yeo EL, Tang LC, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomised comparative trial. Hum Reprod 2000;15:709-712.
15. World Health Organization. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532-537.